Expertise in
5
conditions

Sherko Kummel

Essen, NW, DE 
Expertise in
5
conditions
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Sherko Kummel practices in Essen, Germany. Kummel is highly rated in 5 conditions, according to our data. Their top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and Mastectomy.

Their clinical research consists of co-authoring 146 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Essen, NW, Germany
Other Locations
Berlin, BE, Germany
Moenchengladbach, NW, Germany
Bayreuth, BY, Germany
Hannover, NI, Germany
Koeln, NW, Germany
Munich, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Adj. Dynamic Marker - Adjusted Personalized Therapy Comparing Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy in (Clinical or Genomic) High Risk, HR+/HER2- EBC
Adj. Dynamic Marker - Adjusted Personalized Therapy Comparing Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy in (Clinical or Genomic) High Risk, HR+/HER2- EBC
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 3
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: ladiratuzumab vedotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
PRO-Pocket - International Prospective Multicenter Post Market Clinical Follow Up to Patient Reported Outcome in Primary or Secondary Breast Reconstruction After Mastectomy Using a Titanised Polypropylene Mesh (TiLOOP® Bra Pocket)
PRO-Pocket - International Prospective Multicenter Post Market Clinical Follow Up to Patient Reported Outcome in Primary or Secondary Breast Reconstruction After Mastectomy Using a Titanised Polypropylene Mesh (TiLOOP® Bra Pocket)
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Device
A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype
A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype
Enrollment Status: Completed
Publish Date: May 15, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Trastuzumab Biosimilar ABP 980, Pertuzumab
Study Phase: Phase 2
Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)
Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

146 Total Publications

600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kummel's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile